Rajam S. Mani

Edmonton, AB, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Correction: F2,6BP restores mitochondrial genome integrity in Huntington's disease.

Correction: F2,6BP restores mitochondrial genome integrity in Huntington's disease.

Journal: The Journal of biological chemistry

Published: June 10, 2026

F2,6BP restores mitochondrial genome integrity in Huntington's disease.

F2,6BP restores mitochondrial genome integrity in Huntington's disease.

Journal: The Journal of biological chemistry

Published: August 01, 2025

F2,6BP restores mitochondrial genome integrity in Huntington's Disease.

F2,6BP restores mitochondrial genome integrity in Huntington's Disease.

Journal: bioRxiv : the preprint server for biology

Published: November 22, 2024

Modulation of ERCC1-XPF Heterodimerization Inhibition via Structural Modification of Small Molecule Inhibitor Side-Chains.

Modulation of ERCC1-XPF Heterodimerization Inhibition via Structural Modification of Small Molecule Inhibitor Side-Chains.

Journal: Frontiers in oncology

Published: November 21, 2021

Mutations of the DNA repair gene PNKP in a patient with microcephaly, seizures, and developmental delay (MCSZ) presenting with a high-grade brain tumor.

Mutations of the DNA repair gene PNKP in a patient with microcephaly, seizures, and developmental delay (MCSZ) presenting with a high-grade brain tumor.

Journal: Scientific reports

Published: October 10, 2021

A synthetically lethal nanomedicine delivering novel inhibitors of polynucleotide kinase 3'-phosphatase (PNKP) for targeted therapy of PTEN-deficient colorectal cancer.

A synthetically lethal nanomedicine delivering novel inhibitors of polynucleotide kinase 3'-phosphatase (PNKP) for targeted therapy of PTEN-deficient colorectal cancer.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: December 08, 2020

Design, synthesis and in vitro cell-free/cell-based biological evaluations of novel ERCC1-XPF inhibitors targeting DNA repair pathway.

Design, synthesis and in vitro cell-free/cell-based biological evaluations of novel ERCC1-XPF inhibitors targeting DNA repair pathway.

Journal: European journal of medicinal chemistry

Published: June 08, 2020

Targeting DNA Repair in Tumor Cells via Inhibition of ERCC1-XPF.

Targeting DNA Repair in Tumor Cells via Inhibition of ERCC1-XPF.

Journal: Journal of medicinal chemistry

Published: August 02, 2019

Domain analysis of PNKP-XRCC1 interactions: Influence of genetic variants of XRCC1.

Domain analysis of PNKP-XRCC1 interactions: Influence of genetic variants of XRCC1.

Journal: The Journal of biological chemistry

Published: May 31, 2018

The Rev1 interacting region (RIR) motif in the scaffold protein XRCC1 mediates a low-affinity interaction with polynucleotide kinase/phosphatase (PNKP) during DNA single-strand break repair.

The Rev1 interacting region (RIR) motif in the scaffold protein XRCC1 mediates a low-affinity interaction with polynucleotide kinase/phosphatase (PNKP) during DNA single-strand break repair.

Journal: The Journal of biological chemistry

Published: July 13, 2017

Structural and functional characterization of the PNKP-XRCC4-LigIV DNA repair complex.

Structural and functional characterization of the PNKP-XRCC4-LigIV DNA repair complex.

Journal: Nucleic acids research

Published: November 29, 2016

Showing 1-11 of 11

Last Updated: 09/26/2026